CoChat
Sign Up
Cited by 633Cardiovascular Function and Risk FactorsHeart Failure Treatment and ManagementCardiomyopathy and Myosin Studies

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community

Wang, Thomas J., Evans, Jane C., Benjamin, Emelia J., Levy, Daniel, LeRoy, Elizabeth C., Vasan, Ramachandran S.·2003·Circulation
DOI 10.1161/01.cir.0000085166.44904.79
Open this paper in CoChat — free account

Abstract

Background— Information is limited regarding the rates of progression to congestive heart failure (CHF) and death in individuals with asymptomatic left ventricular systolic dysfunction (ALVD). We sought to characterize the natural history of ALVD, by studying unselected individuals with this condition in the community. Methods and Results— We studied 4257 participants (1860 men) from the Framingham Study who underwent routine echocardiography. The prevalence of ALVD (visually estimated ejection fraction [EF]≤50% without a history of CHF) was 6.0% in men and 0.8% in women. During up to 12 years of follow-up, rates of CHF among subjects with normal left ventricular systolic function (EF >50%, n=4128) and ALVD (n=129) were 0.7 and 5.8 per 100 person-years, respectively. After adjustment for cardiovascular disease risk factors, ALVD was associated with a hazards ratio (HR) for CHF of 4.7 (95% CI 2.7 to 8.1), compared with individuals without ALVD. An elevated risk of CHF after ALVD was observed even in individuals without prior myocardial infarction or valvular disease, with an adjusted HR of 6.5 (CI 3.1 to 13.5). Mild ALVD (EF 40% to 50%, n=78) and moderate-to-severe ALVD (EF <40%, n=51) were associated with adjusted HRs for CHF of 3.3 (CI 1.7 to 6.6) and 7.8 (CI 3.9 to 15.6), respectively. ALVD was also associated with an increased mortality risk (adjusted HR 1.6, CI 1.1 to 2.4). The median survival of ALVD subjects was 7.1 years. Conclusion— Individuals with ALVD in the community are at high risk of CHF and death, even when only mild impairment of EF is present. Additional studies are needed to define optimal therapy for mild ALVD.

Overview

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000085166.44904.79

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 3

  1. 10.1161/circ.81.4.2138525 · DOI
  2. 10.1161/circ.100.9.999 · DOI
  3. 10.1161/circ.98.21.2282 · DOI

Cited by

Sorted by citations

Items 601–633 of 633

Related

See all

Metadata

Authors
Wang, T. J., Evans, J. C., Benjamin, E. J., Levy, D., LeRoy, E. C., & Vasan, R. S.
Affiliations
Boston University (US)
ORCID
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2003-08-26
Volume
108
Issue
8
Pages
977-982
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
DOI
10.1161/01.cir.0000085166.44904.79
OpenAlex
W2095689312
Semantic Scholar
c0b4cca1f7420447dfabc94c7398e07a3c8a6163
Cited by
633
References
24
Citations by year
2026: 21 · 2025: 21 · 2024: 28 · 2023: 22 · 2022: 20 · 2021: 45 · 2020: 31 · 2019: 36 · 2018: 29 · 2017: 39 · 2016: 32 · 2015: 21 · 2014: 28 · 2013: 37 · 2012: 36
FWCI
11.05
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5k23hl074077-03, 5k24hl004334-08, n01hc25195-41-0-1, 5r01ns017950-40)
  • National Heart, Lung, and Blood Institute (K23 HL074077-01, K24-HL-04334-01A1, N01‐HC25195)
  • National Institute of Neurological Disorders and Stroke (5-R01-NS-17950)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
Keywords
natural history (disease), congestive heart failure, mortality risk, ejection fraction, Framingham Heart Study, community-based cohort, disease progression
MeSH terms
Adult, Aged, Aged, 80 and over, Echocardiography, Female, Follow-Up Studies, Heart Failure, Humans, Male, Massachusetts, Middle Aged, Risk Factors, Stroke Volume, Systole, Cohort Studies, Comorbidity, Incidence, Prevalence, Survival Rate, Proportional Hazards Models, Age of Onset, Age Distribution, Disease Progression, Ventricular Dysfunction, Left, Risk Assessment, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review